Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides

1. A compound or salt thereof, of formula (IIIa) or (IIIb):

where

R 1 is selected from the group consisting of substituted or unsubstituted C 2-8 alkyl, substituted or unsubstituted C 1-8 alkoxy, substituted or unsubstituted C 1-8 alkylamino, and substituted or unsubstituted C 3-10 heterocyclyl;

R 2 is H, F, Cl, or substituted or unsubstituted C 1-8 alkoxy; or

R 1 and R 2 together with the carbon atoms to which they are attached form a non-aromatic carbocyclic ring or a heterocyclic ring;

R 3 is H, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 1-8 alkoxy, or halo;

R 4 is H or F;

R 5 is H, F, Cl, or —CH 3 ;

R 6 is H, halo, —CN, —CO 2 R a , —CONH 2 , —NH 2 , substituted or unsubstituted C 1-8 aminoalkyl, substituted or unsubstituted C 1-8 alkyl, or substituted or unsubstituted C 1-8 alkoxy;

R a is H or substituted or unsubstituted C 1-8 alkyl;

or where R 5 and R 6 together with the carbon atoms to which they are attached form a carbocyclic ring;

each R 8 is independently selected from the group consisting of H, halo, —CN, —OH, oxo, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 1-8 alkoxy, and —NR 20 R 21 , substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;

R 20 and R 21 are each independently H, or substituted or unsubstituted C 1-8 alkyl; and

n is 0, 1, 2 or 3.

2. The compound of claim 1 or salt thereof, where

R 1 is selected from the group consisting of: —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —C(CH 3 ) 2 CH 2 CH 3 , —C(CH 2 CH 2 )CN, —C(OH)(CH 3 ) 2 , —OCH 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2 , —OC(CH 3 ) 3 , —OCH 2 CH(CH 3 ) 2 , —OCF 3 , and morpholino;

R 2 is H, F, or Cl; or

R 1 and R 2 may together form —OC(CH 3 ) 2 CH 2 — or —C(CH 3 ) 2 CH 2 CH 2 —;

R 3 is H, —CH 3 , or —OCH 3 ;

R 4 is H or F;

R 5 is H;

R 6 is H, —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C 3 H 7 , —CH 2 F, —CHF 2 , —CF 2 CH 3 , —CF 3 , —CH 2 OCH 3 , —CH 2 OH, —CH 2 CN, —CN, or —CONH 2 ; and

each R 8 is independently selected from the group consisting of H, F, Cl, Br, —CH 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —NH 2 , —N(CH 3 ) 2 , and —CN.

3. The compound of claim 2 or salt thereof, where R 1 is —C(CH 3 ) 3 .

4. The compound of claim 3 or salt thereof, where

R 2 is H or F;

R 3 is H;

R 4 is H; and

R 6 is —CH 3 , —CH 2 F, —CHF 2 , or —CF 3 .

5. The compound of claim 4 or salt thereof, selected from the group consisting of:

6. A compound or salt, selected from the group consisting of

and N-oxides thereof.

7. A composition comprising a pharmaceutically acceptable carrier and a compound or salt of claim 1 .

8. A method of modulating CCR(9) function in a cell, comprising contacting the cell with a CCR(9) modulating amount of the compound of claim 1 .

9. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, an inflammatory hepatic disease, and post-operative ileus.

10. The method of claim 9 , wherein the subject is a human.

11. The method of claim 9 , where the administering is oral, parenteral, rectal, transdermal, sublingual, nasal or topical.

12. The method of claim 9 , where the CCR(9)-mediated disease or condition is an inflammatory bowel disease selected from Crohn's disease and ulcerative colitis.

13. The method of claim 9 , wherein the CCR(9)-mediated condition or disease is selected from primary sclerosing cholangitis and post-operative ileus.

14. The method of claim 13 , wherein the primary sclerosing cholangitis is subsequent to or associated with an inflammatory bowel disease.

15. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 2 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, an inflammatory hepatic disease, primary sclerosing cholangitis, and post-operative ileus.

16. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 5 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, an inflammatory hepatic disease, primary sclerosing cholangitis, and post-operative ileus.

17. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 6 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, an inflammatory hepatic disease, primary sclerosing cholangitis, and post-operative ileus.

18. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 15 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, primary sclerosing cholangitis, and post-operative ileus.

19. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 16 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, primary sclerosing cholangitis, and post-operative ileus.

20. A method for treating a CCR(9)-mediated condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 17 , wherein the CCR(9)-mediated disease or condition is selected from an inflammatory bowel disease, primary sclerosing cholangitis, and post-operative ileus.